StockpollyBeta
Get App
Popularity #3,502
CUE · NASDAQ · Biotechnology

Cue Biopharma (CUE)

Develops immune-modulating biologics for autoimmune and allergic diseases.

$32.08
vs last close+1.18 (+3.82%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue2223320322268
Cost of revenue9130000000000
Gross profit−7−1223320322268
5214131211131210201196
Research & development101110109798517749
5234344453447
Selling & marketing1−3−1000000000
General & administrative4544344453447
Other expenses−10−111000000000
Operating income−11−14−13−10−9−10−12−9−82−5−88
00000000000−65
Interest income111000000000
Interest expense010000000000
Other non-operating income00−1000000000
Income before tax−11−13−12−10−9−9−12−8−72−5−153
Income tax expense000000000100
Net income from continuing operations−11−13−12−10−9−9−12−8−72−5−153
Net income−11−13−12−10−9−9−12−8−72−5−153
EPS, basic−$7.20−$8.40−$7.50−$6.00−$5.10−$3.90−$5.10−$2.66−$2.21$0.44−$1.08−$24.14
EPS, diluted−$7.20−$8.40−$7.50−$6.00−$5.10−$3.90−$5.10−$2.66−$2.21$0.43−$1.08−$24.14
Weighted average shares, basic222222233456
Weighted average shares, diluted222222233456
EBITDA−11−14−11−9−8−9−11−8−73−4−88
Depreciation & amortization001110110110
EBIT−11−14−12−10−8−9−12−8−72−5−88